The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

(2009) C. M. Santamaria et al.   BLOOD

Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia

(2008) Christina A. Ortmann et al.   ANNALS OF HEMATOLOGY

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

(2008) K. Rezvani et al.   BLOOD

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

PRAME expression and clinical outcome of breast cancer

(2008) M T Epping et al.   BRITISH JOURNAL OF CANCER

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

(2008) C. Santamaria et al.   HAEMATOLOGICA

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

(2008) A S M Yong et al.   LEUKEMIA

Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells

(2008) D L Stirewalt et al.   LEUKEMIA

Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2in vitroandin vivo

(2008) Nicolas Tajeddine et al.   LEUKEMIA & LYMPHOMA